Want to see AU:CC5 full AI Analyst Report?
Top Page
LBT Innovations Limited
(Sydney:CC5)
Select Model
Select Model
Rating:42Neutral
Price Target:
AU$0.02
▼(-20.00% Downside)
Action:Reiterated
Date:09/08/26
Overall score is held down primarily by weak financial performance, highlighted by FY2026 margin collapse, a return to losses, and ongoing cash burn/negative free cash flow. Technical signals are mixed but lean weak given the stock remains below key long-term moving averages and has a negative MACD. Valuation is also constrained because losses create a negative P/E and there is no dividend yield data.
Positive Factors
Moderate leverage
Current leverage appears moderate rather than excessively debt-funded, which gives the company some financial flexibility while it addresses operating weakness. A manageable debt burden can reduce interest-related pressure and preserve capacity for restructuring or selective investment over the next several quarters.
Negative Factors
Revenue and margin collapse
The simultaneous decline in revenue and move to negative gross profit signal severe operating deterioration, with costs outpacing sales at the core business level. This weakens confidence in sustainable unit economics and suggests that restoring growth alone may not be enough without meaningful cost or pricing improvement.
Read all positive and negative factors
Positive Factors
Negative Factors
Moderate leverage
Current leverage appears moderate rather than excessively debt-funded, which gives the company some financial flexibility while it addresses operating weakness. A manageable debt burden can reduce interest-related pressure and preserve capacity for restructuring or selective investment over the next several quarters.
Read all positive factors
LBT Innovations Limited (CC5) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$40.37M
Dividend YieldN/A
Average Volume (3M)799.43K
Price to Earnings (P/E)―
Beta (1Y)1.53
Revenue Growth-15.42%
EPS Growth-210.00%
CountryAU
Employees26
SectorTechnology
Sector Strength88
IndustrySoftware - Infrastructure
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding2,182,255,100
10 Day Avg. Volume613,638
30 Day Avg. Volume799,435
Financial Highlights & Ratios
PEG Ratio0.10
Price to Book (P/B)6.27
Price to Sales (P/S)10.22
P/FCF Ratio-18.29
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)<0.01
Revenue Forecast (FY)AU$4.00M
LBT Innovations Limited Business Overview & Revenue Model
Company Description
Based in Adelaide, Australia, Clever Culture Systems Limited, established in 2004, focuses on the innovation, development, and market launch of advanced technological solutions for the medical industry. The company operates internationally, servin...
LBT Innovations Limited Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
55
Neutral
Cash Flow
22
Negative
| Breakdown | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 4.62M | 5.46M | 1.26M | 2.13M | 2.13M |
| Gross Profit | -1.98M | 3.96M | 1.11M | 1.71M | 1.33M |
| EBITDA | -3.73M | 220.00K | -4.05M | -17.12M | -5.72M |
| Net Income | -2.24M | 1.68M | -3.74M | -22.52M | -6.64M |
Balance Sheet | |||||
| Total Assets | 13.55M | 10.77M | 7.93M | 7.37M | 31.52M |
| Cash, Cash Equivalents and Short-Term Investments | 1.70M | 1.26M | 2.35M | 2.02M | 2.79M |
| Total Debt | 2.98M | 2.21M | 3.19M | 3.39M | 4.29M |
| Total Liabilities | 6.02M | 5.12M | 5.51M | 7.47M | 10.19M |
| Stockholders Equity | 7.52M | 5.64M | 2.42M | -105.00K | 21.34M |
Cash Flow | |||||
| Free Cash Flow | -2.58M | 1.13M | -3.68M | -1.40M | -5.00M |
| Operating Cash Flow | -2.57M | 1.16M | -3.67M | -1.40M | -4.95M |
| Investing Cash Flow | -475.00K | -2.33M | -6.00K | -305.00K | -1.24M |
| Financing Cash Flow | 3.48M | 83.00K | 4.01M | 935.00K | -637.00K |
LBT Innovations Limited Technical Analysis
Positive
0.02
Price Trends
0.02
Positive
0.02
Positive
0.02
Negative
Market Momentum
<0.01
Positive
55.28
Neutral
200.00
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:CC5, the sentiment is Positive. The current price of 0.02 is below the 20-day moving average (MA) of 0.02, above the 50-day MA of 0.02, and below the 200-day MA of 0.02, indicating a neutral trend. The MACD of <0.01 indicates Positive momentum. The RSI at 55.28 is Neutral, neither overbought nor oversold. The STOCH value of 200.00 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:CC5.
LBT Innovations Limited Peers Comparison
UnderperformOutperform
Sector (61)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
64 Neutral | AU$30.81M | 0.81 | 265.43% | 106.25% | -24.21% | ― | |
61 Neutral | $37.18B | 12.37 | -10.20% | 1.83% | 8.50% | -7.62% | |
57 Neutral | AU$41.78M | 97.68 | 1.06% | 12.96% | 4.73% | ― | |
48 Neutral | AU$10.73M | -1.48 | -162.05% | ― | -11.66% | 89.02% | |
42 Neutral | AU$40.37M | -18.00 | -43.22% | ― | -15.42% | -210.00% | |
41 Neutral | AU$15.49M | -7.82 | -26.53% | ― | -42.68% | 32.10% | |
40 Underperform | AU$10.04M | -10.00 | 147.62% | ― | -29.96% | -12.50% |
* Technology Sector Average
AU:CC5
LBT Innovations Limited
0.02
-0.02
-45.45%
AU:SEN
Senetas Corporation Limited
2.56
-0.04
-1.54%
AU:QFE
QuickFee Ltd.
0.08
0.04
122.22%
AU:PIL
Peppermint Innovation Limited
0.01
0.00
0.00%
AU:CYB
Sovereign Cloud Holdings Ltd.
0.05
-0.03
-37.80%
AU:TAL
HSC Technology Group Ltd.
0.05
-0.04
-48.28%
LBT Innovations Limited Corporate Events
Clever Culture Systems Wins Expanded Novo Nordisk Order as APAS Nears Global Validation
Sep 7, 2026
Clever Culture Systems Ltd, an Adelaide-based specialist in AI microbiology automation, has secured a new purchase order from Novo Nordisk for two additional APAS® Independence instruments, lifting the pharma group’s installed base to t...
Clever Culture Systems Files Appendix 4G, Confirms Governance Compliance
Aug 31, 2026
Clever Culture Systems Ltd has lodged its Appendix 4G and confirmed that its corporate governance statement for the year to 30 June 2026 is available on its website, as required under ASX listing rules. The statement, current as at 31 August 2026 ...
Clever Culture Systems Tightens Governance and Diversity Framework
Aug 31, 2026
Clever Culture Systems has outlined its adherence to the ASX Corporate Governance Council’s fourth‑edition principles, detailing board responsibilities, delegation to the CEO and key decisions reserved for directors, as well as process...
Clever Culture Systems expands global footprint for FDA-cleared AI lab platform
Aug 31, 2026
Clever Culture Systems has positioned its APAS Independence platform as a best-in-class, AI-driven tool for automated culture plate reading in microbiology, and it is currently the only artificial intelligence technology cleared by the U.S. FDA fo...
Clever Culture Systems Swings to Loss as Revenue Falls and Costs Rise
Aug 31, 2026
Clever Culture Systems reported a sharp deterioration in its 2026 financial performance, with revenue falling 29.6% to $4.67 million and the group swinging from a prior-year profit to a $2.24 million net loss. The decline was driven by lower incom...
Clever Culture Systems Seeks ASX Quotation for 2.6 Million New Shares
Aug 13, 2026
Clever Culture Systems Limited has applied for quotation of 2,632,340 new ordinary fully paid shares on the Australian Securities Exchange, with an issue date of 13 August 2026. The securities, issued under a previously announced transaction, will...
Clever Culture Systems Director Adjusts Equity Holdings as Options Expire
Aug 13, 2026
Clever Culture Systems has reported a change in the interests of director Brenton Barnes, following the expiry and lapse of 1.5 million unlisted options with an exercise price of $0.157 on 7 August 2026. Despite this disposal, Barnes maintains sub...
Clever Culture Systems Options Lapse, Trim Potential Dilution
Aug 10, 2026
Clever Culture Systems Limited has announced the cessation of 1,500,000 options that expired unexercised on 7 August 2026, identified as options expiring on various dates at various prices. The expiry of these options without conversion slightly r...
Clever Culture Systems Plans November Share Placement on ASX
Aug 6, 2026
Clever Culture Systems Limited has notified the ASX of a proposed placement of up to 2,468,170 ordinary fully paid shares. The new securities, carrying the CC5 ticker, are planned for issue on 30 November 2026 as part of an adjustment to the compa...
Clever Culture Systems Plans New Share Placement on ASX
Aug 5, 2026
Clever Culture Systems Limited has notified the ASX of a proposed placement of up to 2,632,340 ordinary fully paid shares. The company has lodged the required Appendix 3B information, confirming its intention to have the new securities quoted in l...
Clever Culture Systems Doubles Pharma Customer Base and Builds APAS® Sales Pipeline
Jul 30, 2026
Clever Culture Systems reported a strong FY26 expansion of its APAS® Independence footprint in the pharmaceutical sector, doubling the number of large global pharma customers to eight and lifting its installed base to 34 instruments. New leas...
Clever Culture Systems Issues 16 Million Unquoted Options to Support Capital Strategy
Jul 1, 2026
Clever Culture Systems Limited has notified the ASX of the issue of 16 million unquoted options, each exercisable at $0.033 and expiring on June 30, 2028, with an issue date of July 1, 2026. These options, which are not intended to be quoted on th...
Clever Culture Systems Plans New ASX-Listed Options Issue
Jun 29, 2026
Clever Culture Systems Limited has outlined a proposed placement involving the issue of up to 16,765,000 new options, each expiring on 30 June 2028 with an exercise price of A$0.033. The options are to form a new class of securities on the ASX, wi...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.